Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

09/22/2020 | 07:55am EST

Item 8.01 Other Events.

On September 22, 2020, bluebird bio, Inc. ("bluebird") and Bristol Myers Squibb Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review their Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121), the companies' investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.

The full text of bluebird's press release is being furnished as Exhibit 99.1 to this Current Report on Form 8­K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
    Exhibit
      No.                                             Description
     99.1               Press release issued by bluebird bio, Inc. on September 22, 2020  .
                      Cover Page Interactive Data File (embedded within the Inline XBRL document)





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about BLUEBIRD BIO, INC.
11/24BLUEBIRD BIO : Announces Live Webcast to Review Clinical Data Presented at the A..
BU
11/19BLUEBIRD BIO : Corporate Presentation - November 2020
PU
11/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
11/10BLUEBIRD BIO : Announces November Investor Events
BU
11/05BLUEBIRD BIO : to Present Data from Gene and Cell Therapy Programs During the 62..
BU
11/04BLUEBIRD : 3Q Earnings Snapshot
AQ
11/04BLUEBIRD BIO : Management's Discussion and Analysis of Financial Condition and R..
AQ
11/04BLUEBIRD BIO : Reports Third Quarter 2020 Financial Results and Highlights Opera..
BU
11/04BLUEBIRD BIO, INC. : Results of Operations and Financial Condition, Financial St..
AQ
10/02BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news